Differential miRNA signatures in Hepatitis E Virus Infection: Insights into acute, chronic, and pregnancy-related outcomes.

IF 3 3区医学 Q2 INFECTIOUS DISEASES

European Journal of Clinical Microbiology & Infectious Diseases Pub Date : 2025-10-01 Epub Date: 2025-07-14 DOI:10.1007/s10096-025-05207-4

Nancy León-Janampa, Julien Marlet

{"title":"Differential miRNA signatures in Hepatitis E Virus Infection: Insights into acute, chronic, and pregnancy-related outcomes.","authors":"Nancy León-Janampa, Julien Marlet","doi":"10.1007/s10096-025-05207-4","DOIUrl":null,"url":null,"abstract":"Purpose: Hepatitis E virus (HEV) is a positive single-stranded RNA virus that causes acute and chronic hepatitis with severe complications in pregnant women and immunocompromised individuals. HEV infection manifest asymptomatically or progress to fulminant hepatitis, liver failure, and extrahepatic manifestations such as neurological disorders and renal damage. MicroRNAs are non-coding RNA molecules that play a key role in diseases and viral pathogenesis, influencing viral replication and immune evasion through their interaction with host factors. In this review, we discuss the role of microRNAs described to date in hepatitis E infection, highlighting their impact on acute, chronic, and pregnancy-related clinical outcomes.Results: miR-122, miR-214, miR-221, and miR-222 participate in the HEV replication and immune evasion, while specific miRNA profiles distinguish acute and chronic hepatitis E. HEV poses severe risks in pregnancy, with miR-431, miR-654, and miR-1468 related to self-limiting infection, and miR-450b to acute liver failure. Studying these miRNAs lead to biomarkers and therapies for hepatitis E.","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"2303-2321"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484267/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Microbiology & Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10096-025-05207-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hepatitis E virus (HEV) is a positive single-stranded RNA virus that causes acute and chronic hepatitis with severe complications in pregnant women and immunocompromised individuals. HEV infection manifest asymptomatically or progress to fulminant hepatitis, liver failure, and extrahepatic manifestations such as neurological disorders and renal damage. MicroRNAs are non-coding RNA molecules that play a key role in diseases and viral pathogenesis, influencing viral replication and immune evasion through their interaction with host factors. In this review, we discuss the role of microRNAs described to date in hepatitis E infection, highlighting their impact on acute, chronic, and pregnancy-related clinical outcomes.

Results: miR-122, miR-214, miR-221, and miR-222 participate in the HEV replication and immune evasion, while specific miRNA profiles distinguish acute and chronic hepatitis E. HEV poses severe risks in pregnancy, with miR-431, miR-654, and miR-1468 related to self-limiting infection, and miR-450b to acute liver failure. Studying these miRNAs lead to biomarkers and therapies for hepatitis E.

查看原文本刊更多论文

戊型肝炎病毒感染的不同miRNA特征：对急性、慢性和妊娠相关结果的见解

目的：戊型肝炎病毒（HEV）是一种阳性单链RNA病毒，可在孕妇和免疫功能低下个体中引起急性和慢性肝炎，并伴有严重并发症。HEV感染表现为无症状或进展为暴发性肝炎、肝功能衰竭和肝外表现，如神经障碍和肾损害。MicroRNAs是一种非编码RNA分子，在疾病和病毒发病过程中发挥关键作用，通过与宿主因子的相互作用影响病毒复制和免疫逃避。在这篇综述中，我们讨论了迄今为止描述的微小rna在戊型肝炎感染中的作用，强调了它们对急性、慢性和妊娠相关临床结果的影响。结果：miR-122、miR-214、miR-221和miR-222参与HEV复制和免疫逃避，而特异性miRNA谱区分急性和慢性戊型肝炎。HEV在妊娠期具有严重风险，miR-431、miR-654和miR-1468与自限性感染有关，miR-450b与急性肝衰竭有关。研究这些mirna有助于开发戊型肝炎的生物标志物和治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Microbiology & Infectious Diseases 医学-传染病学

CiteScore

10.40

自引率

2.20%

发文量

138

审稿时长

1 months

期刊介绍： EJCMID is an interdisciplinary journal devoted to the publication of communications on infectious diseases of bacterial, viral and parasitic origin.